Womens Health Diagnostics Market Segmentation:
Type Segment Analysis
The diagnostic imaging segment is projected to hold a dominant 32% revenue share by the end of 2037. The growth is driven by the growing incidence of breast cancer and the broader screening guidelines being put in place. According to the U.S. Preventive Services Task Force (USPSTF), it’s now standard for women aged 40 to 74 to get mammograms every two years. This has led to a significant boost in screening rates. Additionally, the use of digital breast tomosynthesis is on the rise around the world.
Technology Segment Analysis
The molecular diagnostics segment is poised to account for 23% revenue share in the market due to the growing need for precision medicine. The use of molecular diagnostics (PCR, NGS, microarrays) provides highly accurate detection and identification of genetic disorders, human papillomavirus (HPV), and prenatal conditions, supporting personalized health care practices. Those molecular tests are considered the gold standard of detection for high-risk HPV strains associated with cervical cancer. Next-generation sequencing (NGS) and CRISPR-based diagnostic testing can increase the speed and affordability of testing.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegments |
|
Type |
|
|
Technology |
|
|
Application |
|
|
End-User |
|
